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Aim To investigate if conjugated linoleic acid supplemen-
tation (CLA) affects metabolic factors and oxidative stress 
in non-alcoholic fatty liver disease (NAFLD).
Methods The study was a randomized, controlled clinical 
trial conducted in specialized and subspecialized clinics of 
Tabriz University of Medical Sciences from January 2014 to 
March 2015. 38 obese NAFLD patients were randomly al-
located into either the intervention group, receiving three 
1000 mg softgel of CLA with a weight loss diet and 400 IU 
vitamin E, or into the control group, receiving only weight 
loss diet and 400 IU vitamin E for eight weeks. Dietary data 
and physical activity, as well as anthropometric, body com-
position, metabolic factors, and oxidative stress were as-
sessed at baseline and at the end of the study.
Results Weight, body composition, and serum oxida-
tive stress, insulin, and lipid profile significantly improved 
in both groups, while hemoglobin A1c (HbA1c) levels 
(P = 0.004), total cholesterol to high density lipoprotein 
ratio (P = 0.008), low density lipoprotein to high density 
lipoprotein ratio (LDL/HDL) (P = 0.002), and alanine amin-
otransferase to aspartate aminotransferase (ALT/AST) ratio 
(P = 0.025) significantly decreased in the intervention group. 
At the end of the study, fat mass (P = 0.001), muscle mass 
(P = 0.023), total body water (P = 0.004), HbA1c (P < 0.001), 
triglycerides (P = 0.006), LDL/HDL ratio (P = 0.027), and ALT/
AST ratio (P = 0.046) were significantly better in the CLA 
group than in the control group.
Conclusion CLA improved insulin resistance, lipid distur-
bances, oxidative stress, and liver function in NAFLD. There-
fore, it could be considered as an effective complementary 
treatment in NAFLD.
Registration number: IRCT2014020516491N1.
Conjugated linoleic acid 
improves glycemic response, 
lipid profile, and oxidative 
stress in obese patients 
with non-alcoholic fatty 
liver disease: a randomized 
controlled clinical trial
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Non-alcoholic fatty liver disease (NAFLD) is the most com-
mon chronic liver disease characterized by the accumula-
tion of large droplets of triglycerides within hepatocytes, 
contributing to more than 5% of liver weight, in the ab-
sence of chronic alcohol consumption (1-3). It encom-
passes a spectrum of pathologic conditions, from simple 
steatosis to steatohepatitis, cirrhosis, and rarely hepatocel-
lular carcinoma (3). The estimated prevalence of NAFLD in 
the general population is 20%-30%, increasing to 70%-90% 
among obese and diabetic patients (3). Its prevalence in 
Asian countries varies from 9%-40% (4). NAFLD is strongly 
associated with obesity, type 2 diabetes, dyslipidemia, and 
hypertension (5) and is thus considered to be the hepatic 
manifestation of metabolic syndrome (6).
The pathogenesis of NAFLD is not completely understood, 
but it can be explained by the multi-hit hypothesis, the first 
hit being steatosis, triggered by insulin resistance, the sec-
ond hit being oxidative stress and inflammation, resulting 
in disease progression (7,8), and the third hit being hepato-
cyte proliferation progenitors impairment (9).
Although there are no specific guidelines for NAFLD treat-
ment, it is recommended to treat the associated factors by 
weight reduction, glycemic control, and lipid control (7,10). 
Therefore, functional foods such as bioactive lipids seem to 
play a role in modulating metabolism and body weight (7). 
A specific group of 18 carbon poly-unsaturated fatty acids, 
known as conjugated linoleic acid (CLA) – a mixture of po-
sitional and geometric conjugated isomers of linoleic acid 
(11,12) – has been shown to regulate energy metabolism 
and is commercially being used as a weight loss supple-
ment (7). Considerable attention has been paid to biologi-
cal activates of CLA, which act as a potential therapeutic 
nutrient through their effects on insulin resistance, hyper-
lipidemia, and controlling oxidative status (13-15).
Recent studies have shown that trans-10, cis-12 CLA iso-
mer reduces body weight and fat accumulation (16) and 
in some cases increases insulin resistance, impairs blood 
glucose and lipid profile (15,17-20), and increases oxidative 
stress and inflammation (21). However, the effects of cis-9, 
trans-11 and 50:50 isomers are controversial.
Animal studies have shown that CLA supplementation re-
duces body weight and body fat mass and improves gly-
cemic status and lipid profiles (22-27), but the results in 
humans are inconsistent (14,22,25-32). CLA has shown 
no significant effects on lipid profile, fasting blood glu-
cose, insulin resistance, body composition, and body 
mass index (BMI) among healthy and hyperlipidemic over-
weight and obese participants (28,29), as well as diabetic 
patients (14). In diabetic patients, CLA supplementation (3 
g/d) showed negative effects on insulin and glucose me-
tabolism and positive effects on serum HDL metabolism 
(13), triacylglycerol (TAG), and very low density lipopro-
teins (VLDL), but did not affect any other biochemical pa-
rameters (33). However, in another study it improved body 
composition, serum glucose, and insulin concentrations 
without having significant effects on lipid profile (34). In 
addition, CLA supplementation had no significant effects 
on lipid peroxidation and antioxidant metabolism among 
healthy volunteers (35), but had beneficial effects on oxi-
dative stress among atherosclerotic patients (36).
Therefore, as NAFLD prevalence is increasing worldwide 
and studies investigating the effects of CLA supplemen-
tation on patients with NAFLD are rare and inconsistent, 
we aimed to examine whether weight loss diet with and 
without CLA supplementation had an effect on insulin re-




This randomized controlled clinical trial was conducted 
from January 2014 to March 2015. 234 participants referred 
to the specialized and subspecialized clinics of Tabriz Uni-
versity of Medical Sciences underwent ultrasonography 
by a single sonographist for determining fatty liver. Ac-
cording to the Saverymuttu method (37), the degree of 
fatty liver was classified as: “mild,” “moderate,” and “severe.” 
The study protocol was approved by the Ethics Commit-
tee of Tabriz University of Medical Sciences and was reg-
istered at the Iranian Registry of Clinical Trials website 
(IRCT2014020516491N1). Written informed consent was 
obtained from each participant.
Sample size was estimated to be 19 participants in each 
group, considering 20% change in mean Quicki index re-
ported by Shadman et al (14) using Pocock formula and 
confidence level of 95% (α = 0.05) and power of 90% 
(β = 0.10).
Patients confirmed as NAFLD were assessed based on 
the inclusion criteria, ie, 20-50 years of age, BMI between 
30-40 kg/m2, and taking 400 international units (IU) of vi-
tamin E supplement daily. Exclusion criteria were alcohol 
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consumption; pregnancy or lactation, being menopausal 
and athlete; inflammatory conditions such as infection; hy-
pertension; family history of hyperlipidemia; cardiovascu-
lar disease, lung, renal or liver disease; liver transplantation; 
biliary disease; known autoimmune disease; cancer; burns 
and injuries during the study; surgery in the last 3 months; 
use of medications such as antihypertensives, insulin sensi-
tivity enhancers, hepatotoxic drugs, statins, contraceptive 
pills, and estrogens, as well as vitamin and mineral supple-
ments, and antioxidant supplementation in the last two 
months. This left 28 and 26 participants in the control and 
CLA group, respectively (totally 54 patients).
study design
Demographic characteristics and disease history were ob-
tained. All patients received 400 IU/d vitamin E supplement 
as routine treatment. The patients were randomly allocated 
into two groups based on BMI, sex, and NAFLD grade using 
random block (n = 4): the intervention group receiving CLA 
80% soft gel 1000 mg supplied by Nutrifit (Nutricentury, 
Markham, ON, Canada, containing both cis-9, trans-11, and 
trans-10, cis-12 type CLAs in equal proportion) three times 
per day with a weight loss diet meal and the control group 
receiving weight loss diet only for eight weeks (Figure 1). 
The CLA dosage used in this study has been shown to be 
non- toxic and without side effects (38-40). Each patient re-
ceived their supplements in 4 batches, every 2 weeks. The 
person who determined allocation sequence for the study 
and those who assigned participants were blinded. The 
person who analyzed the data was also blinded.
A food frequency questionnaire (FFQ) (36) for assessing ha-
bitual diet was completed at baseline. For weight loss diet, 
individual energy requirement was estimated based on the 
current weight using Harris-Benedict formula (41) minus 
700 kcal with the 55:30:15% of energy from C:F:P. All partici-
pants were asked to maintain their usual diet and lifestyle 
habits. 16 participants could not adhere to the protocol be-
cause of travel, diseases not related to CLA, discontinued 
intervention because of failure to follow diet recommenda-
tion, and irregular consumption of supplements due to the 
lack of attention. They were excluded from the study.
Anthropometric and body composition measurement
Weight and height were measured using Seca scale (Ham-
burg, Germany) and non-stretchable tape to the nearest 
100 g and 0.5 cm, respectively, after which BMI was esti-
mated. Waist and hip circumferences were measured after 
expiration at the midpoint between the lowest rib and the 
iliac crest and at the widest point between the hip and the 
buttock to the nearest 0.5 cm, respectively. Waist to hip ra-
tio (WHR) and waist to height ratio (WHtR) were estimat-
FiguRE 1. Flowchart of the study.
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ed. Body composition was assessed at the beginning and 
end of the study using body analyzer (Tanita BC-418 Body 
Composition Analyzer, Arlington Heights, IL, USA)
dietary assessment
Mean daily dietary intake was assessed through fulfilling 
a three 3-day food records at baseline, week 4, and week 
8. Home measurements and scales were used to quantify 
the portion sizes. Energy and macronutrients intakes were 
analyzed using Nutritionist IV software (ver. 3.5.2, San Bru-
no, CA, USA).
Physical activity measurement
Three physical activity questionnaires (1) were completed 
at baseline, week 4, and the end of intervention and re-
ported as metabolic equivalents (MET) per day.
Biochemical measurements
10-mL fasting blood samples were taken at the beginning 
and end of the study. Aliquots of serum were collected in 
micro tubes and stored at -70°C until analysis. Serum ala-
nine aminotransferase (ALT), aspartate aminotransferase 
(AST), fasting blood glucose (FBS), insulin, lipid profile (to-
tal cholesterol [TC], low density lipoprotein cholesterol 
[LDL-C], high density lipoprotein cholesterol [HDL-C], and 
triglycerides [TG]), and oxidative stress indices (total anti-
oxidant capacity [TAC], arylesterase [ARE], and malondial-
dehyde [MDA]). Liver enzymes were measured using Inter-
national Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) method (Biosystem, Barcelona, Spain kit) 
using autoanalyzer instrument (Hitachi 911 Depok, Indo-
nesia). Lipid profile and FBS were measured using commer-
cial kits and enzymatic colorimetric method (Parsazmun, 
Tehran, Iran) with autoanalyzer (Abbot, Model Alycon 300, 
USA). LDL-C was calculated using the Friedwald formula 
(42). Insulin was measured using enzyme linked immune 
assay (ELISA) commercial kit (Monobind Inc. Lake Forest, 
CA, USA). Insulin resistance (IR) was determined using the 
homeostasis model assessment (HOMA). HOMA-IR and 
Quantitive Insulin Sensitivity Check Index (Quicki) scores 
were calculated using the following formulas (14):
HOMA-IR = fasting blood glucose (mmol/L) × serum insulin 
(μU/mL) /22.5
Quicki = 1/log fasting blood glucose (mmol/L) + log se-
rum insulin (μU/mL)
Spectrophotometry method with phenylacetate as a sub-
strate was applied to measure serum ARE activity. TAC was 
measured using spectrophotometry method with Randox 
TAS kit (radical ABTS; Randox Laboratories, Antrim, United 
Kingdom). However, spectrophotometry technique for 
MDA assessment was based on its reaction with thiobar-
bituric acid.
statistical analysis
All statistical analyses were performed using SPSS software 
(ver. 16.0, SPSS Inc., Chicago, IL, USA). The normality of dis-
tribution of continuous variables was tested using Kolmog-
orov-Smirnov test. Data for normally distributed variables 
are shown as mean ± standard deviation. Independent t 
test was used to compare the variable means between the 
two groups and analysis of covariance (ANCOVA) was ap-
plied for adjusting the covariates. To compare the change 
in the studied variables over the study period in each 
group, paired t test and Wilcoxon rank t test were used. A 
repeated measure analysis was also applied to assess the 
changes in dietary intakes and physical activity over the 
study period. P-<0.050 was considered as significant.
REsults
38 of 54 patients (19 in each group) completed the study 
(Figure 1). At baseline, there were no significant differ-
ences between the groups in age (36.74 ± 6.87 years and 
38.58 ± 8.24 years in intervention and control group, re-
spectively), sex, marital status, education level, and sever-
ity of fatty liver disease (Table 1). The control group had 
significantly greater mean weight, waist and hip circumfer-
ences than CLA group (P = 0.031, P = 0.030, and P = 0.015, 
respectively), Thus, these factors were considered as co-
variates in the analysis (Table 2). At the end of the study, 
anthropometric measurements decreased significantly in 
both groups, but there were no significant differences be-
tween the groups. Fat mass, muscle mass, and total body 
water improved significantly after the study in the CLA 
group compared to the control group (P = 0.001, P = 0.023, 
and P = 0.004, respectively).
There were no differences in energy and macronutri-
ent intakes between the two groups at baseline, week 4, 
and week 8, except for fat intake, which was significantly 
higher at week 8 in the CLA group (P = 0.019). Significant 
change in total energy intake in the control group was 
considered as a confounder in advanced analysis. Re-
peated measure analysis found no significant changes in 
335Ebrahimi-Mameghani et al: CLA improves metabolic factors in obese patients with NAFLD
www.cmj.hr
physical activity (expressed as MET/d) over the study pe-
riod (Table 3).
At baseline, the groups had similar glycemic index and liv-
er enzyme, while CLA group had significantly higher to-
tal cholesterol (P = 0.042). At the end of the study, fasting 
glucose concentration non-significantly decreased in CLA 
group. HbA1c significantly decreased in the CLA group dur-
ing the study (P = 0.004) and after the intervention it was 
lower than in the control group (P < 0.001). Insulin signifi-
cantly increased during the study in both groups (P = 0.024 
and P = 0.020 in the control and CLA group, respectively). 
HOMA-IR score significantly increased at week 8 compared 
to baseline in the control group (P < 0.001), while it de-
creased non-significantly in the CLA group. Quicki index in-
creased non-significantly in both groups. Also, total choles-
terol levels, triglycerides, and LDL significantly decreased in 
both groups, and TC/LDL and LDL/HDL ratios significantly 
decreased only in the CLA group (P = 0.008 and P = 0.002, 
respectively). Also, TG and LDL/HDL ratio significantly de-
creased in the CLA group compared to the control group 
(P = 0.006 and 0.027, respectively). ALT/AST ratio signifi-
cantly decreased in the CLA group (P = 0.025). While this 
ratio non-significantly increased in the control group, the 
reduction in ALT/AST ratio in CLA group was significantly 
higher than in the control group (P = 0.046) (Table 4).
discussion
To our knowledge, this is the first study investigating the 
effects of CLA in combination with vitamin E and low-calo-
rie diet in patients with NAFLD disease. We found that CLA 
supplementation improved body composition, lipid pro-
file, oxidative stress, liver function, and serum HbA1c.
In our study, CLA group had decreased insulin resistance 
assessed by HOMA-IR, which might be attributed to energy 
expenditure, increasing peroxisome proliferators-activated 
receptor (PPARγ) expression – acting as a ligand for this re-
ceptor (22) and adiponectin production (43). Our findings 
were similar to a study on sedentary women with metabol-
ic syndrome (44), healthy women (34), and diabetic patients 
(13). However, in most studies in humans, CLA supplemen-
tation had no effect on glycemic status and lipid profile 
(14,25,29,31,32). In the present study, CLA supplementa-
tion improved lipid profile and significantly reduced serum 
TG levels (12.25%) and LDL/HDL ratio (16.88%), which was 
shown to be the best single predictor of cardiovascular dis-
ease (45). Therefore, the effect of CLA supplementation on 
LDL/HDL cholesterol in NAFLD patients may be of clinical 
benefit. Maloney et al (13) showed that a similar dose of 
CLA in a similar study period as in our study significantly 
reduced LDL/HDL cholesterol ratio among type 2 diabetic 
patients. Another study showed that CLA supplementation 
significantly improved plasma TG levels in normo-lipidemic 
participants (33), while no changes in serum total choles-
terol, HDL, LDL, and triglyceride level were found among 
healthy women (34). In contrast, 5.5 g/d CLA for 16 weeks 
increased serum TG and TC/HDL ratio and decreased HDL-C 
among postmenopausal women (46). The inconsistency 
in results may be due to differences in study populations, 
CLA dose, and the intervention period. The hypotriacylg-
lycerol effect of CLA might be explained by the fact that 
CLAs are potent agonists of PPARs, including PPARα, which 
is the key transcription factor regulating hepatic lipid me-
tabolism, and PPARγ, which regulates the expression of the 
genes determining adipogenesis, lipid metabolism, and in-
sulin sensitivity. Some other proposed mechanisms affect 
peroxisome proliferators-sterol regulatory element-binding 
proteins (SREBPs), and stearoyl-CoA desaturase (SCD). SREB-
P1c isoforms regulate fatty acid and TG synthesis (47).
The present study found non-significant reductions in 
ALT serum levels (28.16%), however the change in ALT/
tABlE 1. Baseline characteristics of the group treated with conjugated linoleic acid and controls
characteristic
control 
(n = 19) (%)
conjugated linoleic acid 
(n = 19) (%) P*
Female 84.2  89.5 0.999
single 89.5 100 0.486
Educational level
before high school and high school 57.9  57.9 0.999
university degree 42.1  42.1
severity of fatty liver
mild 78.9  68.4 0.461
moderate and severe 21.1  31.6
*χ2 test.
CLINICAL SCIENCE336 Croat Med J. 2016;57:331-42
www.cmj.hr
tABlE 2. Anthropometric measurements and body composition before and after conjugated linoleic acid supplementation (ci – con-
fidence interval, Md – mean difference)
Variable
control 
(n = 19, mean ± standard deviation)
conjugated linoleic acid 
(n = 19, mean ± standard deviation) P
Height (cm) 159.24 ± 6.67 158.81 ± 8.93 0.867†
Bone   2.726 ± 0.378   2.942 ± 0.373 0.105†
Weight (kg)
before  89.36 ± 9.34  82.10 ± 10.60 0.031†
after  84.84 ± 9.56  77.30 ± 10.45 0.559‡
MD (CI 95%)   4.5 (3.71 to 5.28)   4.80 (4.10 to 5.50)
P* <0.001 <0.001
Body mass index (kg/m2)
before  35.27 ± 3.46  32.72 ± 4.63 0.064†
after  33.50 ± 3.63  30.80 ± 4.45 0.460‡
MD (CI 95%)   1.77 (1.46 to 2.07)   1.97 (1.26 to 2.22)
P* <0.001 <0.001
Waist circumference (cm)
before 109.28 ± 9.92 103.18 ± 6.34 0.030†
after 103.70 ± .10.34  97.34 ± 7.01 0.952‡
MD (CI 95%)   5.58 (4.63 to 6.53)   5.84 (4.72 to 6.96)
P* <0.001 <0.001
Hip circumference (cm)
before 119.73 ± 7.89 113.68 ± 6.75 0.015†
after 116.11 ± 8.19 109.08 ± 7.09 0.342‡
MD (CI 95%)   4.60 (3.45 to 5.57)   3.63 (2.69 to 5.56)
P* <0.001 <0.001
Waist to hip ratio
before   0.91 ± 0.047   0.90 ± 0.047 0.804†
after   0.89 ± 0.066   0.89 ± 0.054 0.530‡
MD (CI 95%)   0.02 (0.01 to 0.021)   0.01 (0.00 to 0.02)
P* <0.001 <0.001
Waist to height ratio
before   0.68 ± 0.067   0.65 ± 0.053 0.080†
after   0.65 ± 0.069   0.61 ± 0.054 0.778‡
MD (CI 95%)   0.03 (0.02 to 0.04)   0.03 (0.02 to 0.04)
P* <0.001 <0.001
Fat mass (%)
before  46.71 ± 6.35  46.05 ± 5.71 0.737†
after  45.55 ± 6.69  41.43 ± 6.46 0.001‡
MD (CI 95%)   1.16 (0.39 to 1.93)   4.61 (2.81 to 6.41)
P* 0.005 <0.001
Muscle mass (%)
before  32.44 ± 4.36  33.92 ± 2.57 0.210†
after  33.02 ± 4.34  35.55 ± 2.79 0.023‡
MD (CI 95%)  -0.63 (-0.82 to -0.44)   -1.63 (-2.39 to -0.88)
P* 0.001 <0.001
total body water
before  36.31 ± 4.35  36.04 ± 3.90 0.846†
after  38.14 ± 4.59  38.14 ± 4.41 0.004‡




‡Analysis of covariance (AncoVA) adjusted for baseline values and energy intake.
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AST ratio (12.5%) was significant. Although there is a lim-
ited number of studies examining the effect of CLA mix 
on liver function, Nagoa et al (43) found that 8-week diet 
containing 1% CLA significantly decreased serum AST and 
ALT levels in obese, diabetic Zucker rats. Another study also 
found that CLA consumption significantly reduced serum 
ALT concentration in Zucker rats (27). On the other hand, 
a study in healthy non-obese sedentary women, similar-
ly to our study, failed to show any significant difference in 
serum ALT levels (48). The effect of CLA on liver function 
could be due to the enhancement of adiponectin produc-
tion (43).
ARE is synthesized by the liver and hydrolyzes organo-
phosphate compounds in mammals (49). In our study, 
serum ARE levels increased significantly in both groups, 
but no significant difference was shown between the 
two groups. There is a limited number of studies exam-
ining the effects of CLA supplementation on serum ARE 
levels. Ariyaeian et al (47) reported no significant differ-
ence in serum ARE level between patients with rheuma-
toid arthritis who received supplementation with 2gr CLA 
+ 400 mg vitamin E and those who received corn oil for 
three months. In the present study, serum MDA levels de-
creased significantly and TAC increased significantly with-
out any differences between the groups. The studies on 
Sprague-Dawley rats and mice (15,50) showed that CLA 
significantly reduced MDA levels. In addition, Aliasghari 
et al (36) reported a significant reduction of MDA after 
CLA supplementation in atherosclerosis. The effect of 
CLA on oxidative stress improvement might be explained 
by its antioxidant activity (51), induction of the activity of 
antioxidant enzymes (52), and decreasing lipid peroxida-
tion (53).
This study has several limitations. It was not possible to es-
timate dietary intake and serum CLA concentration. We 
also had a relatively small sample size, short follow-up pe-
riod, and did not use placebo in the control group. There-
fore, further long-term placebo-controlled clinical trials are 
tABlE 3. daily total energy and macronutrient intakes and physical activity
Variable
control 
(n = 19, mean ± standard deviation)
conjugated linoleic acid 
(n = 19, mean ± standard deviation) P*
Energy (kcal)
week 0 1272.71 ± 292.33 1120.68 ± 306.25 0.126
week 4 1124.09 ± 334.92 1154.96 ± 252.81 0.757
week 8 1157.18 ± 340.92 1171.45 ± 325.60 0.897
P† 0.020 0.921
carbohydrate (g)
week 0  192.73 ± 56.51  161.67 ± 56.57 0.099
week 4  176.57 ± 59.45  165.09 ± 35.30 0.416
week 8  182.85 ± 69.23  163.72 ± 42.53 0.321
P† 0.441 0.833
Protein (g)
week 0   52.70 ± 14.03   49.96 ± 13.92 0.510
week 4   51.44 ± 14.21   49.77 ± 12.20 0.708
week 8   48.35 ± 10.40   48.19 ± 12.55 0.887
P† 0.298 0.808
Fat (g)
week 0   30.71 ± 8.09   31.90 ± 9.41 0.680
week 4   28.20 ± 12.19   35.83 ± 13.26 0.081
week 8   26.88 ± 7.98   34.90 ± 11.67 0.019
P† 0.213 0.435
Physical activity (metabolic equivalents /d)
week 0   36.41 ± 4.20   38.27 ± 2.69 0.117
week 4   36.06 ± 4.12   38.69 ± 2.61 0.027
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(n = 19, mean ± standard deviation)
conjugated linoleic acid 
(n = 19, mean ± standard deviation) P
Fasting blood glucose (mg/dl)
before  96.16 ± 10.43 102.26 ± 18.05 0.210†
after  98.47 ± 11.29  98.68 ± 10.26 0.683‡
MD (CI 95%)   1.16 (0.39 to 1.93)   4.61 (2.81 to 6.41)
P* 0.074 0.392
Hemoglobin A1c (%)
before   4.57 ± 0.08   4.49 ± 0.77 0.774†
after   4.74 ± 0.88   3.99 ± 0.63 <0.001‡
MD (CI 95%)  -0.17 (-0.36 to 0.02)   0.50 (0.17 to 0.83)
P* 0.077 0.004
insulin (μiu/ml)
before  13.87 ± 7.34  13.37 ± 4.04 0.797†
after  14.55 ± .7.45  13.89 ± 4.25 0.423‡
MD (CI95%)  -0.67 (-1.25 to -1.00)  -0.51 (-0.94 to -0.09)
P* 0.024 0.020
Homeostatic model assessment-insulin 
resistance
before   3.26 ± 1.77   3.4 ± 1.33 0.795†
after   3.50 ± 1.83   3.39 ± 1.12 0.178‡
MD (CI 95%)   -0.23 (-0.03 to -0.12)   0.006 (-0.26 to 0.27)
P* <0.001 0.096
Quantitative insulin sensitivity check index
before   1.57 ± 0.29   1.60 ± 0.15 0.669†
after   1.59 ± 0.26   1.62 ± 0.14 0.495‡
MD (CI 95%)   -0.02 (-0.06 to 0.001)   -0.01 (-0.09 to 0.00)
P* 0.080 0.053
cholesterol(mg/dl)
before 188.74 ± 27.76 213.11 ± 41.66 0.042†
after 176.95 ± 24.62 203.37 ± 39.51 0.179‡
MD(CI 95%)  11.78 (6.26 to 17.31)   9.737 (1.75 to 17.21)
P* <0.001 0.020
triglyceride(mg/dl)
before 164.05 ± 92.27 149.42 ± 63.60 0.573†
after 143.95 ± 81.69 110.15 ± 48.46 0.006‡
MD (CI 95%)  20.10 (7.098 to 33.11)  39.26 (27.54 to 50.99)
P* 0.004 <0.001
low density lipoprotein (mg/dl)
before  25.23 ± 26.73 138.53 ± 33.13 0.182†
after 115.58 ± .24.72 122.80 ± 29.53 0.616‡
MD (CI 95%)   9.65 (5.02 to 14.28)  15.72 (6.16 to 25.28)
P* <0.001 0.003
High density lipoprotein (mg/dl)
before  45.95 ± 7.46  49.63 ± 15.41 0.354†
after  44.89 ± 9.86  51.95 ± 16.90 0.114‡
MD (CI 95%)   1.05 (-1.20 to 3.31)  -2.31 (-6.87 to 2.24)
P*   0.34 0.300
total cholesterol/high density lipoprotein
before   4.19 ± 0.77   4.72 ± 1.88 0.259†
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required to study the effect CLA supplementation. Due to 
insufficient information regarding molecular mechanisms 
of CLA in humans, human cell culture studies are also rec-
ommended.
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after   4.09 ± 0.9   4.26 ± 1.52 0.150‡
MD (CI 95%)   0.09 (-0.06 to 0.24)   0.46 (0.13 to 0.79)
P* 0.277 0.008
low density lipoprotein /high density 
lipoprotein
before   2.79 ± 0.68   3.08 ± 1.28 0.380†
after   2.70 ± 0.84   2.56 ± 0.93 0.027‡
MD (CI 95%)   0.08(-0.07 to 0.23)   0.52 (0.22 to 0.83)
P* 0.270 0.002
Aspartate aminotransferase (iu/l)
before  18.26 ± 3.94  19.89 ± 17.36 0.405†
after  18.05 ± 3.14  17.33 ± 4.21 0.375‡
MD (CI 95%)   0.21 (-1.50 to 1.93)   2.55 (-0.41 to 5.52)
P* 0.800 0.087
Alanine aminotransferase (iu/l)
before  22.37 ± 9.04  24.82 ± 23.01 0.798†
after  31.74 ± 28.24  17.83 ± 10.40 0.086‡
MD (CI 95%)  -8.36 (-22.04 to 5.30)   7 (-1.16 to 15.16)
P* 0.81 0.215
Alanine aminotransferase/ aspartate 
aminotransferase
before   1.24 ± 0.31   1.12 ± 0.44 0.340†
after   1.81 ± 1.95   0.98 ± 0.39 0.046||
P* 0.159 0.025
total antioxidant capacity (mmol/l)
before   1.36 ± 0.31  1.21 ± 0.34 0.182†
after   1.58 ± 0.38  1.32 ± 0.42 0.285‡
MD (CI 95%)   -0.22 (-0.36 to -0.07)  -0.0/1 (-0.2 to 0.01)
P* 0.005 0.028
Aryl esterase (u/l)
before 111.0 ± 29.85 118.89 ± 28.41 0.409†
after 124.26 ± 30.99 133.68 ± 21.54 0.694‡
MD (CI 95%)  -13.26 (-20.05 to -6.47)  -14.78 (-23.05 to -6.53)
P* 0.001 0.001
Malondialdehyde (mmol/ml)
before   2.57 ± 0.61   2.87 ± 1.10 0.314†
after   2.31 ± 0.57   2.38 ± 0.59 0.437‡




‡Analysis of covariance (AncoVA) adjusted for baseline values, energy intake, weight circumference and hip circumference.
§Wilcoxon rank t test.
||Mann-Whitney u test.




(n = 19, mean ± standard deviation)
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